ClinicalTrials.gg

Program

RAY121

A development code.

In Hoffmann-La Roche's pipeline, anti-C1s recycling antibody. Its studies are mostly in Antiphospholipid Syndrome, led by Hoffmann-La Roche.

Furthest: phase 1, since Apr 4, 20242 company-led studies, 2 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche22 open or runningphase 1since Apr 4, 2024Apr 4, 2024Mar 31, 2027phase 1 · NCT06371417
  • Named in Hoffmann-La Roche’s own pipeline as CHU anti-C1s recycling antibody, phase 1, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 4, 2024First study: phase 1 study in Antiphospholipid SyndromeFirst studyNCT06371417 · 144 planned · United States, Australia, Austria and more
  2. Nov 27, 2024Phase 1 study in Antiphospholipid SyndromeNCT06723106 · 144 planned · Australia, Austria, Bulgaria and more

Ahead

  1. Mar 31, 2027Primary completion: phase 1 study in Antiphospholipid SyndromeNCT06371417
  2. Feb 28, 2028Primary completion: phase 1 study in Antiphospholipid SyndromeNCT06723106

TargetBeta

“anti-C1s recycling antibody”the company's pipeline, read by Claude · source

Other programs on C1S

ProgramCompanyFurthest phaseStudies
riliprubartSanofiphase 38
SAR446597Sanofiphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06723106Antiphospholipid Syndrome · Australia, Austria, Bulgaria and more1By invitationFeb 28, 2028144
NCT06371417Antiphospholipid Syndrome · United States, Australia, Austria and more1RecruitingMar 31, 2027144

How it is read

Names in the registry

  • “RAY121”, 2 entries

Codes read as this program: RAY121.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.